

trap integration so as to be operatively coupled to a gene that is differentially expressed in progenitor cells of the selected lineage.

48. (Amended) A method according to Claim 42 wherein the selectable marker is introduced into the multipotential cell via random integration of a transgene in which the selectable marker is operatively coupled to a gene that is differentially expressed in progenitor cells of the selected lineage.

49. (Amended) A method according to Claim 42 wherein the multipotential cell is an ES, EG or EC cell and the method comprises forming an embryoid body, or otherwise inducing differentiation of the cells.

50. (Amended) A method according to Claim 49 wherein the differentiated cells are dissociated so as to form a culture comprising individual cells.

REMARKS

I. Status of the Claims

Claims 42-65 are currently pending. Claims 42-54, 58, 64, and 65 (Group I) have been elected for continued prosecution pursuant to a Response to Restriction Requirement dated November 16, 2001. Claims 55-57 and 59-63 have been withdrawn by the Examiner. Applicants note that the Restriction Requirement dated August 16, 2001 specified that claims 42-51 and Claim 58 link invention I (claims 42-54, 58, 64 and 65), invention II (claims 42-51, 55 and 58), invention III (claims 42-51 and 56-58) and invention IV (claims 42-51 and 58-60). The Examiner has acknowledged that upon allowance of the linking claims, the restriction requirement as to the linked inventions

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000